New Directions in Thyroid Care: Minimizing Risk, Maximizing Choice

From how radioiodine therapy for Graves’ disease impacts cancer occurrence and the potential usefulness of pharmacologic treatment for benign thyroid nodules to how a minimally invasive procedure could be the preferred treatment option, recent studies from The Journal of Clinical Endocrinology & Metabolism further demonstrate how endocrine science is benefiting patients around the world. At a Glance • Systematic review of repurposed drugs identified metformin as the most promising agent for benign thyroid nodule reduction, particularly in patients with metabolic dysfunction, although evidence quality remains insufficient for clinical implementation.

• Percutaneous laser ablation demonstrated sustained thyroid nodule volume reduction — with multiple associated quality-of-life improvements — over a median follow-up of more than 10 years in the largest cohort reported to date. • Radioactive iodine therapy for patients with Graves’ disease was not found to increase the incidence of thyroid cancer, and most thyroid cancers that did develop were micropapillary carcinomas, with no evidence suggesting a poor histologic or genotypical prognosis.